カテゴリ： LP Information, 世界, 医療/バイオ

限局性結節性糸球体硬化症（FSGS）治療薬の世界市場2022-2028：錠剤、カプセル、その他

■ 英語タイトル：Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market Growth 2022-2028
	■ 発行会社/調査会社：LP Information ■ 商品コード：LP22DC4987 ■ 発行日：2022年12月 ■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ■ 産業分野：医薬品 ■ ページ数：121 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後2-3営業日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥549,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥823,500	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,098,000	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[限局性結節性糸球体硬化症（FSGS）治療薬の世界市場2022-2028：錠剤、カプセル、その他]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

限局性結節性糸球体硬化症（FSGS）治療薬のグローバル市場規模は、2021年のxxx百万ドルから2028年までにxxx百万ドルに増加すると推定されており、2022年～2028年の年平均成長率（CAGR）はxx%を示しています。COVID-19とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対するパンデミックの直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
限局性結節性糸球体硬化症（FSGS）治療薬のアジア太平洋市場は、2022年にxxx百万ドルの市場規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。限局性結節性糸球体硬化症（FSGS）治療薬の米国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。限局性結節性糸球体硬化症（FSGS）治療薬のヨーロッパ市場は、2022年にxxx百万ドルの規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。限局性結節性糸球体硬化症（FSGS）治療薬の中国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要な限局性結節性糸球体硬化症（FSGS）治療薬関連企業としては、Travere Therapeutics (Retrophin)、 Novartis、 ZyVersa(Variant)、 Dimerix、 Goldfinch Bio、 ChemoCentryx、 FibroGen、 Pfizer、 AstraZeneca、 Sanofi、 GlaxoSmithKline、 Calliditas、 Reata (AbbVie)、 Astellas Pharma、 Complexa、 Aurinia、 Vertex Pharmaceuticals、 Chinook Therapeutics、 Delta 4、 Langlai Science and Technologyなどをカバーしています。売上の面では世界最大の2社が2021年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながら限局性結節性糸球体硬化症（FSGS）治療薬のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリューチェーン分析などのミクロの詳細にまで及びます。当レポートは読者がパンデミックおよびロシア・ウクライナ戦争中に世界中で限局性結節性糸球体硬化症（FSGS）治療薬市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、限局性結節性糸球体硬化症（FSGS）治療薬のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2021年で、市場の予測は2022年～2028年までのものです。

*** 市場セグメンテーション ***

この調査では限局性結節性糸球体硬化症（FSGS）治療薬市場を細分化し、種類別 (錠剤、カプセル、その他)、用途別 (病院、診療所)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：錠剤、カプセル、その他

・用途別区分：病院、診療所

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：限局性結節性糸球体硬化症（FSGS）治療薬の範囲、調査方法など
第2章：エグゼクティブサマリー、世界の限局性結節性糸球体硬化症（FSGS）治療薬市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2017年～2022年までの推移データ、および2028年までの市場予測
第3章：企業別限局性結節性糸球体硬化症（FSGS）治療薬の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別の限局性結節性糸球体硬化症（FSGS）治療薬の販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界の限局性結節性糸球体硬化症（FSGS）治療薬市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：限局性結節性糸球体硬化症（FSGS）治療薬の年間販売量2017-2028、地域別現状・将来分析
・限局性結節性糸球体硬化症（FSGS）治療薬の種類別セグメント：錠剤、カプセル、その他
・限局性結節性糸球体硬化症（FSGS）治療薬の種類別販売量：2017-2022年の販売量、売上、市場シェア、販売価格
・限局性結節性糸球体硬化症（FSGS）治療薬の用途別セグメント：病院、診療所
・限局性結節性糸球体硬化症（FSGS）治療薬の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界の限局性結節性糸球体硬化症（FSGS）治療薬市場
・企業別のグローバル限局性結節性糸球体硬化症（FSGS）治療薬市場データ：2020-2022年の年間販売量、市場シェア
・企業別の限局性結節性糸球体硬化症（FSGS）治療薬の年間売上：2020-2022年の売上、市場シェア
・企業別の限局性結節性糸球体硬化症（FSGS）治療薬販売価格
・主要企業の限局性結節性糸球体硬化症（FSGS）治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

限局性結節性糸球体硬化症（FSGS）治療薬の地域別レビュー
・地域別の限局性結節性糸球体硬化症（FSGS）治療薬市場規模2017-2022：年間販売量、売上
・主要国別の限局性結節性糸球体硬化症（FSGS）治療薬市場規模2017-2022：年間販売量、売上
・アメリカ州の限局性結節性糸球体硬化症（FSGS）治療薬販売の成長
・アジア太平洋の限局性結節性糸球体硬化症（FSGS）治療薬販売の成長
・ヨーロッパの限局性結節性糸球体硬化症（FSGS）治療薬販売の成長
・中東・アフリカの限局性結節性糸球体硬化症（FSGS）治療薬販売の成長

アメリカ州市場
・アメリカ州の国別の限局性結節性糸球体硬化症（FSGS）治療薬販売量、売上（2017-2022）
・アメリカ州の限局性結節性糸球体硬化症（FSGS）治療薬の種類別販売量
・アメリカ州の限局性結節性糸球体硬化症（FSGS）治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別の限局性結節性糸球体硬化症（FSGS）治療薬販売量、売上（2017-2022）
・アジア太平洋の限局性結節性糸球体硬化症（FSGS）治療薬の種類別販売量
・アジア太平洋の限局性結節性糸球体硬化症（FSGS）治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の限局性結節性糸球体硬化症（FSGS）治療薬販売量、売上（2017-2022）
・ヨーロッパの限局性結節性糸球体硬化症（FSGS）治療薬の種類別販売量
・ヨーロッパの限局性結節性糸球体硬化症（FSGS）治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の限局性結節性糸球体硬化症（FSGS）治療薬販売量、売上（2017-2022）
・中東・アフリカの限局性結節性糸球体硬化症（FSGS）治療薬の種類別販売量
・中東・アフリカの限局性結節性糸球体硬化症（FSGS）治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・限局性結節性糸球体硬化症（FSGS）治療薬の製造コスト構造分析
・限局性結節性糸球体硬化症（FSGS）治療薬の製造プロセス分析
・限局性結節性糸球体硬化症（FSGS）治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・限局性結節性糸球体硬化症（FSGS）治療薬の主要なグローバル販売業者
・限局性結節性糸球体硬化症（FSGS）治療薬の主要なグローバル顧客

地域別の限局性結節性糸球体硬化症（FSGS）治療薬市場予測レビュー
・地域別の限局性結節性糸球体硬化症（FSGS）治療薬市場規模予測（2023-2028）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・限局性結節性糸球体硬化症（FSGS）治療薬の種類別市場規模予測
・限局性結節性糸球体硬化症（FSGS）治療薬の用途別市場規模予測

主要企業分析
Travere Therapeutics (Retrophin)、 Novartis、 ZyVersa(Variant)、 Dimerix、 Goldfinch Bio、 ChemoCentryx、 FibroGen、 Pfizer、 AstraZeneca、 Sanofi、 GlaxoSmithKline、 Calliditas、 Reata (AbbVie)、 Astellas Pharma、 Complexa、 Aurinia、 Vertex Pharmaceuticals、 Chinook Therapeutics、 Delta 4、 Langlai Science and Technology
・企業情報
・限局性結節性糸球体硬化症（FSGS）治療薬製品
・限局性結節性糸球体硬化症（FSGS）治療薬販売量、売上、価格、粗利益（2020-2022）
・主要ビジネス概要
・最新動向

調査の結果

Focal Nodular Glomerulosclerosis (FSGS) is a disease that forms scar tissue on the glomerulus and is an important cause of kidney failure. Focal Glomerular Sclerosis (FSGS) can be caused by a variety of factors.
The global market for Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine players cover Travere Therapeutics (Retrophin), Novartis, ZyVersa(Variant), Dimerix and Goldfinch Bio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

[Report Coverage]
This latest report provides a deep insight into the global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market, with both quantitative and qualitative data, to help readers understand how the Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market and forecasts the market size by Type (Tablet, Capsule and Others), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Tablet
Capsule
Others
Segmentation by application
Hospital
Clinic
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Travere Therapeutics (Retrophin)
Novartis
ZyVersa(Variant)
Dimerix
Goldfinch Bio
ChemoCentryx
FibroGen
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Calliditas
Reata (AbbVie)
Astellas Pharma
Complexa
Aurinia
Vertex Pharmaceuticals
Chinook Therapeutics
Delta 4
Langlai Science and Technology

[Chapter Introduction]
Chapter 1: Scope of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine, Research Methodology, etc.
Chapter 2: Executive Summary, global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market size (sales and revenue) and CAGR, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Travere Therapeutics (Retrophin), Novartis, ZyVersa(Variant), Dimerix, Goldfinch Bio, ChemoCentryx, FibroGen, Pfizer and AstraZeneca, etc.
Chapter 14: Research Findings and Conclusion

*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Country/Region, 2017, 2022 & 2028
2.2 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Segment by Type
2.2.1 Tablet
2.2.2 Capsule
2.2.3 Others
2.3 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type
2.3.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
2.3.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Type (2017-2022)
2.4 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application
2.5.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Market Share by Application (2017-2022)
2.5.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Application (2017-2022)
3 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Company
3.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Breakdown Data by Company
3.1.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales by Company (2020-2022)
3.1.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Company (2020-2022)
3.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Revenue by Company (2020-2022)
3.2.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Company (2020-2022)
3.2.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Company (2020-2022)
3.3 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Company
3.4 Key Manufacturers Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Location Distribution
3.4.2 Players Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Geographic Region
4.1 World Historic Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market Size by Geographic Region (2017-2022)
4.1.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Revenue by Geographic Region
4.2 World Historic Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market Size by Country/Region (2017-2022)
4.2.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Revenue by Country/Region
4.3 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Growth
4.4 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Growth
4.5 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Growth
4.6 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Growth
5 Americas
5.1 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country
5.1.1 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022)
5.1.2 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022)
5.2 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type
5.3 Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Region
6.1.1 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Region (2017-2022)
6.1.2 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Region (2017-2022)
6.2 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type
6.3 APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Country
7.1.1 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022)
7.1.2 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022)
7.2 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type
7.3 Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Country
8.1.1 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022)
8.2 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type
8.3 Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
10.3 Manufacturing Process Analysis of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
10.4 Industry Chain Structure of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Distributors
11.3 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Customer
12 World Forecast Review for Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine by Geographic Region
12.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market Size Forecast by Region
12.1.1 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Forecast by Region (2023-2028)
12.1.2 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Forecast by Type
12.7 Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Forecast by Application
13 Key Players Analysis
13.1 Travere Therapeutics (Retrophin)
13.1.1 Travere Therapeutics (Retrophin) Company Information
13.1.2 Travere Therapeutics (Retrophin) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.1.3 Travere Therapeutics (Retrophin) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Travere Therapeutics (Retrophin) Main Business Overview
13.1.5 Travere Therapeutics (Retrophin) Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.2.3 Novartis Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 ZyVersa(Variant)
13.3.1 ZyVersa(Variant) Company Information
13.3.2 ZyVersa(Variant) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.3.3 ZyVersa(Variant) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 ZyVersa(Variant) Main Business Overview
13.3.5 ZyVersa(Variant) Latest Developments
13.4 Dimerix
13.4.1 Dimerix Company Information
13.4.2 Dimerix Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.4.3 Dimerix Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Dimerix Main Business Overview
13.4.5 Dimerix Latest Developments
13.5 Goldfinch Bio
13.5.1 Goldfinch Bio Company Information
13.5.2 Goldfinch Bio Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.5.3 Goldfinch Bio Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Goldfinch Bio Main Business Overview
13.5.5 Goldfinch Bio Latest Developments
13.6 ChemoCentryx
13.6.1 ChemoCentryx Company Information
13.6.2 ChemoCentryx Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.6.3 ChemoCentryx Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 ChemoCentryx Main Business Overview
13.6.5 ChemoCentryx Latest Developments
13.7 FibroGen
13.7.1 FibroGen Company Information
13.7.2 FibroGen Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.7.3 FibroGen Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 FibroGen Main Business Overview
13.7.5 FibroGen Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.8.3 Pfizer Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 AstraZeneca
13.9.1 AstraZeneca Company Information
13.9.2 AstraZeneca Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.9.3 AstraZeneca Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 AstraZeneca Main Business Overview
13.9.5 AstraZeneca Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.10.3 Sanofi Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
13.11 GlaxoSmithKline
13.11.1 GlaxoSmithKline Company Information
13.11.2 GlaxoSmithKline Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.11.3 GlaxoSmithKline Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 GlaxoSmithKline Main Business Overview
13.11.5 GlaxoSmithKline Latest Developments
13.12 Calliditas
13.12.1 Calliditas Company Information
13.12.2 Calliditas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.12.3 Calliditas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Calliditas Main Business Overview
13.12.5 Calliditas Latest Developments
13.13 Reata (AbbVie)
13.13.1 Reata (AbbVie) Company Information
13.13.2 Reata (AbbVie) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.13.3 Reata (AbbVie) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Reata (AbbVie) Main Business Overview
13.13.5 Reata (AbbVie) Latest Developments
13.14 Astellas Pharma
13.14.1 Astellas Pharma Company Information
13.14.2 Astellas Pharma Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.14.3 Astellas Pharma Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Astellas Pharma Main Business Overview
13.14.5 Astellas Pharma Latest Developments
13.15 Complexa
13.15.1 Complexa Company Information
13.15.2 Complexa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.15.3 Complexa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Complexa Main Business Overview
13.15.5 Complexa Latest Developments
13.16 Aurinia
13.16.1 Aurinia Company Information
13.16.2 Aurinia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.16.3 Aurinia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Aurinia Main Business Overview
13.16.5 Aurinia Latest Developments
13.17 Vertex Pharmaceuticals
13.17.1 Vertex Pharmaceuticals Company Information
13.17.2 Vertex Pharmaceuticals Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.17.3 Vertex Pharmaceuticals Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Vertex Pharmaceuticals Main Business Overview
13.17.5 Vertex Pharmaceuticals Latest Developments
13.18 Chinook Therapeutics
13.18.1 Chinook Therapeutics Company Information
13.18.2 Chinook Therapeutics Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.18.3 Chinook Therapeutics Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 Chinook Therapeutics Main Business Overview
13.18.5 Chinook Therapeutics Latest Developments
13.19 Delta 4
13.19.1 Delta 4 Company Information
13.19.2 Delta 4 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.19.3 Delta 4 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 Delta 4 Main Business Overview
13.19.5 Delta 4 Latest Developments
13.20 Langlai Science and Technology
13.20.1 Langlai Science and Technology Company Information
13.20.2 Langlai Science and Technology Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
13.20.3 Langlai Science and Technology Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales, Revenue, Price and Gross Margin (2020-2022)
13.20.4 Langlai Science and Technology Main Business Overview
13.20.5 Langlai Science and Technology Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Tablet
Table 4. Major Players of Capsule
Table 5. Major Players of Others
Table 6. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type (2017-2022) & (K Units)
Table 7. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
Table 8. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Type (2017-2022) & ($ million)
Table 9. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Type (2017-2022)
Table 10. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application (2017-2022) & (K Units)
Table 12. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Table 13. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Application (2017-2022)
Table 14. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Application (2017-2022)
Table 15. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Company (2020-2022) & (K Units)
Table 17. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Company (2020-2022)
Table 18. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Company (2020-2022)
Table 20. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Producing Area Distribution and Sales Area
Table 22. Players Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Products Offered
Table 23. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share Geographic Region (2017-2022)
Table 28. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country/Region (2017-2022)
Table 32. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022) & (K Units)
Table 35. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country (2017-2022)
Table 36. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country (2017-2022)
Table 38. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type (2017-2022) & (K Units)
Table 39. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
Table 40. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application (2017-2022) & (K Units)
Table 41. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Table 42. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Region (2017-2022) & (K Units)
Table 43. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Region (2017-2022)
Table 44. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Region (2017-2022)
Table 46. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type (2017-2022) & (K Units)
Table 47. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
Table 48. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application (2017-2022) & (K Units)
Table 49. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Table 50. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022) & (K Units)
Table 51. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country (2017-2022)
Table 52. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country (2017-2022)
Table 54. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type (2017-2022) & (K Units)
Table 55. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
Table 56. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application (2017-2022) & (K Units)
Table 57. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Table 67. Key Market Challenges & Risks of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Table 68. Key Industry Trends of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Table 69. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Distributors List
Table 72. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Customer List
Table 73. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Forecast by Region
Table 75. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share Forecast by Application (2023-2028)
Table 93. Travere Therapeutics (Retrophin) Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 94. Travere Therapeutics (Retrophin) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 95. Travere Therapeutics (Retrophin) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Travere Therapeutics (Retrophin) Main Business
Table 97. Travere Therapeutics (Retrophin) Latest Developments
Table 98. Novartis Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 99. Novartis Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 100. Novartis Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. Novartis Main Business
Table 102. Novartis Latest Developments
Table 103. ZyVersa(Variant) Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 104. ZyVersa(Variant) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 105. ZyVersa(Variant) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. ZyVersa(Variant) Main Business
Table 107. ZyVersa(Variant) Latest Developments
Table 108. Dimerix Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 109. Dimerix Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 110. Dimerix Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Dimerix Main Business
Table 112. Dimerix Latest Developments
Table 113. Goldfinch Bio Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 114. Goldfinch Bio Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 115. Goldfinch Bio Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Goldfinch Bio Main Business
Table 117. Goldfinch Bio Latest Developments
Table 118. ChemoCentryx Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 119. ChemoCentryx Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 120. ChemoCentryx Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. ChemoCentryx Main Business
Table 122. ChemoCentryx Latest Developments
Table 123. FibroGen Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 124. FibroGen Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 125. FibroGen Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. FibroGen Main Business
Table 127. FibroGen Latest Developments
Table 128. Pfizer Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 129. Pfizer Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 130. Pfizer Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. Pfizer Main Business
Table 132. Pfizer Latest Developments
Table 133. AstraZeneca Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 134. AstraZeneca Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 135. AstraZeneca Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. AstraZeneca Main Business
Table 137. AstraZeneca Latest Developments
Table 138. Sanofi Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 139. Sanofi Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 140. Sanofi Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. Sanofi Main Business
Table 142. Sanofi Latest Developments
Table 143. GlaxoSmithKline Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 144. GlaxoSmithKline Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 145. GlaxoSmithKline Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. GlaxoSmithKline Main Business
Table 147. GlaxoSmithKline Latest Developments
Table 148. Calliditas Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 149. Calliditas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 150. Calliditas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 151. Calliditas Main Business
Table 152. Calliditas Latest Developments
Table 153. Reata (AbbVie) Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 154. Reata (AbbVie) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 155. Reata (AbbVie) Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 156. Reata (AbbVie) Main Business
Table 157. Reata (AbbVie) Latest Developments
Table 158. Astellas Pharma Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 159. Astellas Pharma Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 160. Astellas Pharma Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 161. Astellas Pharma Main Business
Table 162. Astellas Pharma Latest Developments
Table 163. Complexa Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 164. Complexa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 165. Complexa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 166. Complexa Main Business
Table 167. Complexa Latest Developments
Table 168. Aurinia Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 169. Aurinia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 170. Aurinia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 171. Aurinia Main Business
Table 172. Aurinia Latest Developments
Table 173. Vertex Pharmaceuticals Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 174. Vertex Pharmaceuticals Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 175. Vertex Pharmaceuticals Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 176. Vertex Pharmaceuticals Main Business
Table 177. Vertex Pharmaceuticals Latest Developments
Table 178. Chinook Therapeutics Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 179. Chinook Therapeutics Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 180. Chinook Therapeutics Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 181. Chinook Therapeutics Main Business
Table 182. Chinook Therapeutics Latest Developments
Table 183. Delta 4 Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 184. Delta 4 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 185. Delta 4 Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 186. Delta 4 Main Business
Table 187. Delta 4 Latest Developments
Table 188. Langlai Science and Technology Basic Information, Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Manufacturing Base, Sales Area and Its Competitors
Table 189. Langlai Science and Technology Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Product Offered
Table 190. Langlai Science and Technology Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 191. Langlai Science and Technology Main Business
Table 192. Langlai Science and Technology Latest Developments
List of Figures
Figure 1. Picture of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Figure 2. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Tablet
Figure 10. Product Picture of Capsule
Figure 11. Product Picture of Others
Figure 12. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Type in 2021
Figure 13. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Type (2017-2022)
Figure 14. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Consumed in Hospital
Figure 15. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market: Hospital (2017-2022) & (K Units)
Figure 16. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Consumed in Clinic
Figure 17. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market: Clinic (2017-2022) & (K Units)
Figure 18. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Application (2017-2022)
Figure 19. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Application in 2021
Figure 20. Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market by Company in 2021 ($ Million)
Figure 21. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Company in 2021
Figure 22. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Geographic Region (2017-2022)
Figure 23. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Geographic Region in 2021
Figure 24. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Region (2017-2022)
Figure 25. Global Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country/Region in 2021
Figure 26. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales 2017-2022 (K Units)
Figure 27. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue 2017-2022 ($ Millions)
Figure 28. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales 2017-2022 (K Units)
Figure 29. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue 2017-2022 ($ Millions)
Figure 30. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales 2017-2022 (K Units)
Figure 31. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue 2017-2022 ($ Millions)
Figure 32. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales 2017-2022 (K Units)
Figure 33. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue 2017-2022 ($ Millions)
Figure 34. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country in 2021
Figure 35. Americas Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country in 2021
Figure 36. United States Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 37. Canada Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 38. Mexico Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 39. Brazil Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 40. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Region in 2021
Figure 41. APAC Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Regions in 2021
Figure 42. China Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 43. Japan Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 44. South Korea Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 45. Southeast Asia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 46. India Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Australia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 48. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country in 2021
Figure 49. Europe Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country in 2021
Figure 50. Germany Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 51. France Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 52. UK Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 53. Italy Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Russia Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 55. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Sales Market Share by Country in 2021
Figure 56. Middle East & Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Market Share by Country in 2021
Figure 57. Egypt Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 58. South Africa Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Israel Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 60. Turkey Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 61. GCC Country Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Revenue Growth 2017-2022 ($ Millions)
Figure 62. Manufacturing Cost Structure Analysis of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine in 2021
Figure 63. Manufacturing Process Analysis of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Figure 64. Industry Chain Structure of Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

限局性結節性糸球体硬化症（FSGS）治療薬の世界市場2022-2028：錠剤、カプセル、その他

グローバル市場調査会社